Quantifying Cancer Productivity Losses in Europ...

By HEOR Staff Writer

March 16, 2026

Cancer productivity losses from premature mortality and morbidity due to leading cancers across 28 European countries in 2022 totaled €39.8 billion, as estimated via the human capital approach in
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...